Detalhe da pesquisa
1.
Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.
J Immunol
; 208(1): 54-62, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34853078
2.
Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark.
Br J Clin Pharmacol
; 89(6): 1820-1833, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36519217
3.
Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.
J Infect Dis
; 226(2): 236-245, 2022 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-35104873
4.
Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size.
Clin Infect Dis
; 75(10): 1781-1791, 2022 11 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35396591
5.
Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.
Clin Infect Dis
; 73(7): e1973-e1981, 2021 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33677480
6.
Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.
J Virol
; 92(2)2018 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29118123
7.
Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
J Virol
; 91(9)2017 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28202759
8.
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?
J Virol
; 91(24)2017 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29021399
9.
Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
J Virol
; 91(15)2017 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28539449
10.
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.
PLoS Pathog
; 12(8): e1005745, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-27561082
11.
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.
Clin Infect Dis
; 64(12): 1686-1695, 2017 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28329286
12.
A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
J Virol
; 90(9): 4441-4453, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-26889036
13.
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.
PLoS Pathog
; 11(7): e1005000, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26133551
14.
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
PLoS Pathog
; 11(9): e1005142, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26379282
15.
Toll-like Receptor 7 Agonists in People Living With HIV: Implications for Immunotherapeutic Strategies for an HIV Cure.
Clin Infect Dis
; 72(11): e825-e827, 2021 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33044543
16.
Kick and kill for HIV latency.
Lancet
; 395(10227): 844-846, 2020 03 14.
Artigo
Inglês
| MEDLINE | ID: mdl-32085822
17.
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
J Virol
; 89(20): 10176-89, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26223643
18.
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.
Antimicrob Agents Chemother
; 59(7): 3984-94, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25896701
19.
Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.
Mol Med
; 21: 337-45, 2015 Apr 14.
Artigo
Inglês
| MEDLINE | ID: mdl-25879630
20.
Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients.
Mediators Inflamm
; 2015: 120605, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26696749